Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
Annamaria Ruzzo(University of Urbino), Mauro Magnani(University of Urbino), Francesco Graziano(Ospedale Vincenzo Cervello), Francesca Galli(University of Modena and Reggio Emilia), Enzo Veltri(Ospedale Santa Maria Goretti), Pietro Sozzi(Ospedale degli Infermi), D. Turci(Azienda Ospedaliera San Camillo-Forlanini), Francesca Bergamo(Istituto Oncologico Veneto), Claudio Verusio(Medica (Italy)), L. Frontini, Vittorina Zagonel(Istituto Oncologico Veneto), Irene Bagaloni(University of Urbino), Silvia Lazzarelli(Istituti Ospitalieri di Cremona), Sara Lonardi(Istituto Oncologico Veneto), Eliana Rulli(Mario Negri Institute for Pharmacological Research), Sandro Barni, Annalisa Bramati(Azienda Ospedaliera Fatebenefratelli e Oftalmico), Luisa Foltran(Azienda Ospedaliera Santa Maria Degli Angeli), Edoardo Biondi, Nicoletta Pella(University of Udine), Roberto Labianca(Ospedale Papa Giovanni XXIII), Maura Menghi, Fabio Galli(Mario Negri Institute for Pharmacological Research), B. Massidda(Policlinico Universitario di Catania), Alberto F. Sobrero(Ospedale Policlinico San Martino), Vincenzo Ricci(IRCCS Ospedale San Raffaele), Maria Teresa Ionta(Institute of Genetic and Biomedical Research), Claudia Mucciarini(Azienda Unita' Sanitaria Locale Di Modena), Mario Nicolini(Azienda Ospedaliera Carlo Poma), Monica Ronzoni
Cited by 68
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k